following a re-submission:
miconazole muco-adhesive buccal tablet (Loramyc®) is not recommended for use within NHS Scotland.
Indication under review: The treatment of oropharyngeal candidiasis (OPC) in immunocompromised patients.
Miconazole muco-adhesive buccal tablets were shown to be non-inferior in the treatment of OPC to another locally-acting miconazole preparation in patients with cancer of the head and neck who had received radiotherapy, and to another locally-acting anti-fungal in HIV-positive patients. There are no data comparing miconazole buccal tablets to treatments currently used in practice in Scotland in this patient group.
Overall the manufacturer did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Download detailed advice115KB (PDF)
Medicine details
- Medicine name:
- miconazole (Loramyc)
- SMC ID:
- 517/08
- Indication:
- Treatment of oropharyngeal candidiasis (OPC) in immunocompromised patients (adults only).
- Pharmaceutical company
- Therabel Pharma UK Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 07 February 2011